MedTrace Logo

A Study In Patients With Non-Small Cell Lung Cancer To Test If Erlotinib Plus SU011248 Is Better Than Erlotinib Alone

NCT00457392 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 960

Last updated 2013-10-29

Study results available
· View outcomes & findings →

Summary

This study will test whether treatment with erlotinib plus SU011248 is better than erlotinib alone in patients with advanced/metastatic lung cancer who have received previous treatment with a platinum-based regimen.

Conditions

  • Carcinoma, Non-Small Cell Lung

Interventions

DRUG

erlotinib

plus erlotinib 150 mg daily by tablets in a continuous regimen until progression or unacceptable toxicity

DRUG

sunitinib

Sunitinib 37.5 mg daily by oral capsules in a continuous regimen

DRUG

erlotinib

plus erlotinib 150 mg daily by tablets in a continuous regimen until progression or unacceptable toxicity

DRUG

placebo

Placebo daily by oral capsules in a continuous regimen

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-07-31
Primary Completion
2010-07-31
Completion
2012-12-31

Countries

  • United States
  • Argentina
  • Austria
  • Belgium
  • Brazil
  • Canada
  • Chile
  • Colombia
  • Czechia
  • Denmark
  • Germany
  • Greece
  • Hong Kong
  • Hungary
  • Italy
  • Netherlands
  • Norway
  • Poland
  • Russia
  • Slovakia
  • South Korea
  • Spain
  • Switzerland
  • Taiwan
  • Thailand
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00457392 on ClinicalTrials.gov